Lipid-encapsulated siRNA for hepatocyte-directed treatment of advanced liver disease

Lipid-based RNA nanocarriers have been recently accepted as a novel therapeutic option in humans, thus increasing the therapeutic options for patients. Tailored nanomedicines will enable to treat chronic liver disease (CLD) and end-stage liver cancer, disorders with high mortality and few treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Woitok, Marius Maximilian, Zoubek, Miguel Eugenio, Doleschel, Dennis, Bartneck, Matthias, Mohamed, Mohamed Ramadan, Kießling, Fabian, Lederle, Wiltrud, Trautwein, Christian, Cubero, Francisco Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214425/
https://www.ncbi.nlm.nih.gov/pubmed/32393755
http://dx.doi.org/10.1038/s41419-020-2571-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214425/
https://www.ncbi.nlm.nih.gov/pubmed/32393755
http://dx.doi.org/10.1038/s41419-020-2571-4

Ejemplares similares